New

Obsidian Therapeutics

The AI engine Fit Assessment

Beta

Obsidian Therapeutics develops advanced cell and gene therapies for cancer, offering precise control of protein activity to enhance adoptive immunotherapy using safe, oral drugs.

Blurb

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.

HQ Location

Cambridge (United States)

Founded

2015

Employees

51 - 200

Total funding raised

$325.00M

Last Funding Event

Series C, $160.50M, April 3, 2024

Smart insights

  • 6m headcount growth: 5%
  • 1Y headcount growth: 18%
  • Headcount-to-last-round ratio: 2.4 employees/$M

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies.